Bleeding events with dabigatran or warfarin in patients with venous thromboembolism

Summary

Dabigatran was as effective as warfarin for the acute treatment of venous thromboembolism in the RE-COVER and RE-COVER II trials. We compared the incidence of bleeding with dabigatran versus warfarin in pooled data from these studies. The localisation, bleeding severity, and the impact of key factors on the incidence of bleeding, were compared between the dabigatran and warfarin treatment group. Altogether, 2553 patients received dabigatran and 2554 warfarin, each for a mean of 164 days. The incidence of any bleeding event was significantly lower with dabigatran (hazard ratio [HR] 0.70; 95 % confidence interval [CI], 0.61–0.79), as was the incidence of the composite of MBEs and clinically relevant non-major bleeding events (HR 0.62; 95 % CI, 0.50–0.76). The incidence of major bleeding events (MBEs) was also significantly lower with dabigatran in the double-dummy phase (HR, 0.60; 95 % CI, 0.36–0.99) but not statistically different between the two treatment arms when the entire treatment period is considered (HR 0.73 95 % CI, 0.48–1.11). Increasing age, reduced renal function, Asian ethnicity, and concomitant antiplatelet therapy were associated with higher bleeding rates in both treatment groups. The reduction in bleeding with dabigatran compared to warfarin was consistent among the subgroups and with a similar pattern for intracranial, and urogenital major bleeding. In conclusion, treatment of venous thromboembolism with dabigatran is associated with a lower risk of bleeding compared to warfarin. This reduction did not differ with respect to the location of bleeding or among predefined subgroups.

Keywords

Vitamin K antagonists - dabigatran - venous thromboembolism - bleeding

• References

• 1 Deitelzweig SB, Johnson BH, Lin J. et al. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol 2011; 86: 217-220.
• 2 Michota FA. Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: the quality improvement process. J Gen Intern Med 2007; 22: 1762-1770.
• 3 Spencer FA, Emery C, Lessard D. et al. The Worcester Venous Thromboembol-ism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
• 4 Schulman S, Kakkar AK, Goldhaber SZ. et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-772.
• 5 Schulman S, Kearon C, Kakkar AK. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
• 6 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the S. et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 03: 692-694.
• 7 TIMI definitions for commonly used terms in clinical trials [Oct 1, 2014]. Available from: http://www.timi.org/wp-content/uploads/2010/10/TIMI-Definitions.pdf Accessed October 1, 2014.
• 8 Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacody-namics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (Suppl. 01) 9S-16S.
• 9 Limdi NA, Limdi MA, Cavallari L. et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010; 56: 823-831.
• 10 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomised evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
• 11 EMA.. Pradaxa : EPAR - Product Information 2015 [2015-07-15]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
• 12 Hokusai VTEI, Buller HR, Decousus H. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
• 13 Agnelli G, Buller HR, Cohen A. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
• 14 Prins MH, Lensing AW, Bauersachs R. et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomised studies. Thromb J 2013; 11: 21.
• 15 Bauersachs R, Berkowitz SD, Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
• 16 Graham DJ, Reichman ME, Wernecke M. et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation. 2014 Epub ahead of print.
• 17 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.